View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 4, 2021

SAB Biotherapeutics doses first patient in trial of Covid-19 therapy

The Phase II trial will evaluate the first polyclonal antibody therapeutic candidate SAB-18.

SAB Biotherapeutics has dosed the first patient in the Phase III ACTIV-2 clinical trial to evaluate SAB-185, a fully human polyclonal antibody therapeutic to treat Covid-19.

SAB-18 is a broadly neutralising therapeutic candidate developed using SAB’s DiversitAb platform.

The specifically targeted antibody is intended to treat non-hospitalised patients with mild to moderate Covid-19.

Led by the National Institute of Allergy and Infectious Diseases (NIAID), the ACTIV-2 clinical trial is evaluating the multiple investigational agent to treat the early symptomatic non-hospitalised individuals.

The candidate met the pre-defined efficacy goal and progressed from Phase II to the Phase III part of the ACTIV-2 clinical trial.

It is said to be the first polyclonal antibody therapeutic candidate in the trial and the second agent to advance to Phase III.

SAB Biotherapeutics co-founder, president, and CEO Eddie Sullivan said: “We are delighted that the Phase III trial is underway, just days after the decision by the independent Data Safety Monitoring Board to advance SAB-185 to Phase III.

“The joint decision with NIAID to evaluate the lower dose of SAB-185 in the Phase III trial is a testament to the potency of our human polyclonal antibody therapeutic candidate, which has demonstrated neutralization of multiple emerging SARS-CoV-2 variants in recently published nonclinical studies.”

As part of the randomised, unblinded, active comparator-controlled adaptive platform non-inferiority Phase III study, the company is evaluating SAB-185’s safety and efficacy as against active control monoclonal antibody treatment in Covid-19 patients at higher risk for progression to hospitalisation.

Nearly 600 participants are being enrolled to receive SAB-185 and 600 subjects will be given an active comparator.

Safety and non-inferiority to avoid a composite endpoint of either hospitalisation or death of a subject until study day 28 are included in the trial’s primary outcome measures.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU